Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes

Bioconjugate Chemistry

Volumn 26, Issue 10, 2015, Pages 2062-2069

  Natarajan, Arutselvan ^a   Mayer, Aaron T ^a,b   Xu, Lingyun ^a   Reeves, Robert E ^a   Gano, Jacob ^a   Gambhir, Sanjiv S ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; DERMATOLOGY; DIAGNOSIS; DISEASES; LYMPHOCYTES; MAMMALS; ONCOLOGY; PATIENT MONITORING; PATIENT TREATMENT; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS;

ANTI-TUMOR IMMUNE; CANCER PATIENTS; DIAGNOSTICS AND PROGNOSTICS; IMAGING TOOLS; IMMUNE RESPONSE; IN-VIVO; MALIGNANT MELANOMA; MOST LIKELY; RESPONSE RATE; SOLID TUMORS;

TUMORS;

AMMONIUM ACETATE; CD4 ANTIGEN; COPPER 64; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; TETRAXETAN; TRACER; TRANSCRIPTION FACTOR FOXP3; 2-(4-ISOTHIOCYANATOBENZYL)-1,4,7,10-TETRAAZACYCLODODECANE TETRAACETIC ACID; ANTIBODY CONJUGATE; COPPER; HETEROCYCLIC COMPOUND; ISOTHIOCYANIC ACID DERIVATIVE; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; CD8+ T LYMPHOCYTE; CELL HOMING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DENDRITIC CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOGRAM; IMMUNO POSITRON EMISSION TOMOGRAPHY; IMMUNOREACTIVITY; ISOTOPE LABELING; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PET-CT SCANNER; PROTEIN EXPRESSION; QUALITY CONTROL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; CELL DEATH; CHEMISTRY; DRUG SCREENING; IMMUNOLOGY; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; TISSUE DISTRIBUTION; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL DEATH; COPPER RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; IMMUNOCONJUGATES; ISOTHIOCYANATES; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MICE, TRANSGENIC; POSITRON-EMISSION TOMOGRAPHY; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945555686     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.5b00318     Document Type: Article

References (47)

1. Nguyen, L. T. and Ohashi, P. S. (2014) Clinical blockade of PD1 and LAG3 - potential mechanisms of action Nat. Rev. Immunol. 15, 45-56 10.1038/nri3790
2. Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., and Zang, X. (2015) Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway Trends Mol. Med. 21, 24-33 10.1016/j.molmed.2014.10.009
3. Mellman, I., Coukos, G., and Dranoff, G. (2011) Cancer immunotherapy comes of age Nature 480, 480-9 10.1038/nature10673
4. Rosenberg, S. A. (2004) Development of effective immunotherapy for the treatment of patients with cancer Journal of the American College of Surgeons 198, 685-96 10.1016/j.jamcollsurg.2004.01.025
5. Drake, C. G., Jaffee, E., and Pardoll, D. M. (2006) Mechanisms of immune evasion by tumors Adv. Immunol. 90, 51-81 10.1016/S0065-2776(06)90002-9
6. Fridman, W. H., Pages, F., Sautes-Fridman, C., and Galon, J. (2012) The immune contexture in human tumours: impact on clinical outcome Nat. Rev. Cancer 12, 298-306 10.1038/nrc3245
7. Mullard, A. (2013) New checkpoint inhibitors ride the immunotherapy tsunami Nat. Rev. Drug Discovery 12, 489-92 10.1038/nrd4066
8. Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., and Honjo, T. (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes Int. Immunol. 8, 765-72 10.1093/intimm/8.5.765
9. Zou, W. and Chen, L. (2008) Inhibitory B7-family molecules in the tumour microenvironment Nat. Rev. Immunol. 8, 467-477 10.1038/nri2326
10. Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., and Powderly, J. D. et al. 2014, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J. Clin. Oncol. 32, 1020-30 10.1200/JCO.2013.53.0105
11. Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., and Gibney, G. et al. 2013, Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma J. Clin. Oncol. 31, 4311-8 10.1200/JCO.2013.51.4802
12. Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R. A., and Reed, K. et al. 2013, Nivolumab plus ipilimumab in advanced melanoma N. Engl. J. Med. 369, 122-33 10.1056/NEJMoa1302369
13. Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., and Ahmed, R. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection Nature 439, 682-7 10.1038/nature04444
14. Berghoff, A. S., Ricken, G., Widhalm, G., Rajky, O., Hainfellner, J. A., Birner, P., Raderer, M., and Preusser, M. (2014) PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL) Clinical neuropathology 33, 42-9 10.5414/NP300698
15. Brown, J. A., Dorfman, D. M., Ma, F. R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., and Freeman, G. J. (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production J. Immunol. 170, 1257-66 10.4049/jimmunol.170.3.1257
16. Curran, M. A., Montalvo, W., Yagita, H., and Allison, J. P. (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc. Natl. Acad. Sci. U. S. A. 107, 4275-80 10.1073/pnas.0915174107
17. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., and Tamada, K. et al. 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat. Med. 8, 793-800 10.1038/nm730
18. Franceschini, D., Paroli, M., Francavilla, V., Videtta, M., Morrone, S., Labbadia, G., Cerino, A., Mondelli, M. U., and Barnaba, V. (2009) PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV J. Clin. Invest. 119, 551-64 10.1172/JCI36604
19. Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., and Minato, N. et al. 2007, Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer Proc. Natl. Acad. Sci. U. S. A. 104, 3360-5 10.1073/pnas.0611533104
20. Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., and Weber, J. S. et al. 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369, 134-44 10.1056/NEJMoa1305133
21. Kim, P. S. and Ahmed, R. (2010) Features of responding T cells in cancer and chronic infection Curr. Opin. Immunol. 22, 223-30 10.1016/j.coi.2010.02.005
22. Mamalis, A., Garcha, M., and Jagdeo, J. (2014) Targeting the PD-1 pathway: a promising future for the treatment of melanoma Arch. Dermatol. Res. 306, 511-9 10.1007/s00403-014-1457-7
23. Riley, J. L. (2009) PD-1 signaling in primary T cells Immunol. Rev. 229, 114-25 10.1111/j.1600-065X.2009.00767.x
24. Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., and Gibney, G. et al. 2013, Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma J. Clin. Oncol. 31, 4311-4318 10.1200/JCO.2013.51.4802
25. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., and Mooney, M. et al. 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur. J. Cancer 45, 228-47 10.1016/j.ejca.2008.10.026
26. Kurtz, D. M. and Gambhir, S. S. (2014) Tracking cellular and immune therapies in cancer Adv. Cancer Res. 124, 257-96 10.1016/B978-0-12-411638-2.00008-2
27. Kaufman, H. L., Kirkwood, J. M., Hodi, F. S., Agarwala, S., Amatruda, T., Bines, S. D., Clark, J. I., Curti, B., Ernstoff, M. S., and Gajewski, T. et al. 2013, The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma Nat. Rev. Clin. Oncol. 10, 588-98 10.1038/nrclinonc.2013.153
28. Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., and Rosenberg, S. A. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 114, 1537-44 10.1182/blood-2008-12-195792
29. Chapon, M., Randriamampita, C., Maubec, E., Badoual, C., Fouquet, S., Wang, S. F., Marinho, E., Farhi, D., Garcette, M., and Jacobelli, S. et al. 2011, Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes J. Invest. Dermatol. 131, 1300-7 10.1038/jid.2011.30
30. French, J. D., Kotnis, G. R., Said, S., Raeburn, C. D., McIntyre, R. C., Jr., Klopper, J. P., and Haugen, B. R. (2012) Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer J. Clin. Endocrinol. Metab. 97, E934-43 10.1210/jc.2011-3428
31. Lee, C. M. and Tannock, I. F. (2010) The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors BMC Cancer 10, 255 10.1186/1471-2407-10-255
32. Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., and Shrikant, P. et al. 2010, Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer Proc. Natl. Acad. Sci. U. S. A. 107, 7875-80 10.1073/pnas.1003345107
33. Muenst, S., Soysal, S. D., Gao, F., Obermann, E. C., Oertli, D., and Gillanders, W. E. (2013) The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer Breast Cancer Res. Treat. 139, 667-76 10.1007/s10549-013-2581-3
34. Scott, A. M., Wolchok, J. D., and Old, L. J. (2012) Antibody therapy of cancer Nat. Rev. Cancer 12, 278-87 10.1038/nrc3236
35. Sfanos, K. S., Bruno, T. C., Meeker, A. K., De Marzo, A. M., Isaacs, W. B., and Drake, C. G. (2009) Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+ Prostate 69, 1694-703 10.1002/pros.21020
36. Sun, S., Fei, X., Mao, Y., Wang, X., Garfield, D. H., Huang, O., Wang, J., Yuan, F., Sun, L., and Yu, Q. et al. 2014, PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients Cancer Immunol. Immunother. 63, 395-406 10.1007/s00262-014-1519-x
37. Zhang, Y., Huang, S., Gong, D., Qin, Y., and Shen, Q. (2010) Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer Cell. Mol. Immunol. 7, 389-95 10.1038/cmi.2010.28
38. Shi, F., Shi, M., Zeng, Z., Qi, R. Z., Liu, Z. W., Zhang, J. Y., Yang, Y. P., Tien, P., and Wang, F. S. (2011) PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients Int. J. Cancer 128, 887-96 10.1002/ijc.25397
39. Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., and Anders, R. A. (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin. Cancer Res. 20, 5064-74 10.1158/1078-0432.CCR-13-3271
40. Grosso J, H. C., Inzunza, D., Cardone, D. M., Simon, J. S., and Gupta, A. K. (2013) Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab Journal of Clinical Oncology 31, 3016
41. Herbst, R. S., Gordon, M. S., Fine, G. D., Sosman, J. A., Soria, J. C., and Hamid (2013) A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors Journal of Clinical Oncology 31, 3000
42. Suffner, J., Hochweller, K., Kuhnle, M. C., Li, X., Kroczek, R. A., Garbi, N., and Hammerling, G. J. (2010) Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice J. Immunol. 184, 1810-20 10.4049/jimmunol.0902420
43. Zhou, Q., Munger, M. E., Highfill, S. L., Tolar, J., Weigel, B. J., Riddle, M., Sharpe, A. H., Vallera, D. A., Azuma, M., and Levine, B. L. et al. 2010, Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia Blood 116, 2484-93 10.1182/blood-2010-03-275446
44. Sage, P. T., Francisco, L. M., Carman, C. V., and Sharpe, A. H. (2012) The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood Nat. Immunol. 14, 152-61 10.1038/ni.2496
45. Lipson, E. J., Sharfman, W. H., Drake, C. G., Wollner, I., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., and Chen, L. et al. 2013, Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody Clin. Cancer Res. 19, 462-8 10.1158/1078-0432.CCR-12-2625
46. Natarajan, A. and Gambhir, S. S. (2015) Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography Mol. Imaging Biol. 17, 539 10.1007/s11307-014-0810-8
47. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess J. Immunol. Methods 72, 77-89 10.1016/0022-1759(84)90435-6